Diabetes Care News
-
Showcase
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), ...
-
CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. Among these innovations is the development of coated microneedle preparation technology, which has shown promising results in delivering novel drugs to patients. CD formulation involves coated microneedles with specific drug compounds, allowing for controlled and sustained drug delivery. ...
-
CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. The mechanistic Target of Rapamycin is a serine/threonine protein kinase that is inhibited by rapamycin, a bacterial compound originally isolated from Easter Island soil that ...
-
Vantage Welcomes Roczen!
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
-
Huateng Pharma Introduces Anti-Diabetes Intermediates
Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of anti-diabetes intermediates represents a ...
-
CD BioSciences Launches New Services to Study Catabolism in Diabetes
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new Catabolism research services, which offer researchers a comprehensive range of tools and resources to investigate the role of catabolism in the development and progression of diabetes. Metabolism describes a series of life-sustaining chemical reactions in an organism that convert ...
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine ...
-
CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...
-
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
By Bayer AG
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 ...
By Bayer AG
-
Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
-
New data from pivotal studies with aflibercept 8 mg
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
By Bayer AG
-
BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners
In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands. Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to ...
By BOC Sciences
-
Is HIFU ultrasound treatment safe
Ultrasound HIFU beauty machine is a non-surgical skin tightening treatment, that uses medical aesthetic focused ultrasound technology to bypass the epidermis and heat the energy to 65-70°C and condense it into a large number of extremely fine hot spots. It is a one-time treatment with natural and progressive results that last from one to two years (results vary from person to person), with ...
-
Bayer submits aflibercept 8 mg for marketing authorization in Japan
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with ...
By Bayer AG
-
Alertgy Awarded Patent US20200217809A1 Apparatus For In Vivo Dielectric Spectroscopy
Alertgy has been granted a patent for their innovative and groundbreaking radio frequency sensor technology. The awarded patent, Apparatus for in vivo dielectric spectroscopy (US20200217809A1), focuses on sensor technology that is 100% non-invasive and continuously monitors blood glucose in a way that does not involve blood oxidase, but rather dielectric spectroscopy and radio frequency. As a ...
By Alertgy
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you